Efficacy and safety of statins in primary prevention of cardiovascular disease in adults aged 75 years or older: a Meta-analysis
-
摘要: 目的:系统评价他汀类药物在75岁及以上老年人心血管疾病一级预防中的有效性和安全性。方法:计算机检索PubMed、Embase、Cochrane图书馆、中国知网、中国生物医学文献数据库、维普、万方数据库发表的有关他汀作为75岁及以上老年人心血管病一级预防的随机对照研究或队列研究,检索时间均为建库至2020年12月。使用Stata 15.1软件进行荟萃分析。结果:纳入8项队列研究共394 140例受试者。Meta分析结果显示,在≥2年的随访中,与不使用他汀相比,75岁及以上老年人使用他汀作为心血管病一级预防可能显著降低全因死亡风险(HR=0.81,95%CI:0.71~0.92,P=0.002)、主要血管事件风险(HR=0.84,95%CI:0.75~0.94,P=0.002)和冠心病风险(HR=0.87,95%CI:0.79~0.96,P=0.005),两组缺血性脑卒中风险(HR=0.91,95%CI:0.82~1.01,P=0.081)差异无统计学意义。对于安全性,使用他汀作为心血管病一级预防对75岁及以上老年人糖尿病(HR=0.95,95%CI:0.86~1.05,P=0.329)、肝脏损伤(HR=0.81,95%CI:0.63~1.05,P=0.113)、肌肉损害(HR=0.80,95%CI:0.55~1.17,P=0.25)和肿瘤(HR=0.98,95%CI:0.91~1.05,P=0.603)发生风险的影响未见显著差异。结论:使用他汀进行心血管病一级预防可能显著降低75岁及以上老年人的全因死亡、主要血管事件和冠心病风险,且不增加不良反应的发生,但能否降低缺血性脑卒中风险还需进一步研究。Abstract: Objective: To systematically evaluate the efficacy and safety of statins for primary prevention of cardiovascular disease in adults aged 75 years or older.Methods: We searched PubMed, Embase, Cochrane Library, CNKI, CBM, VIP, and Wanfang databases from inception to December 2020 and collected randomized controlled trials(RCTs) or cohort studies reporting the efficacy and safety of statins for primary prevention of cardiovascular disease in adults aged 75 years or older. Meta-analysis was then performed using Stata 15.1 software.Results: A total of 8 cohort studies involving 394 140 older adults were included. The Meta-analysis indicated that the use of statins in adults aged 75 years or older significantly decreased the risk of all-cause death(HR=0.81, 95%CI: 0.71-0.92, P=0.002), major vascular events(HR=0.84, 95%CI: 0.75-0.94, P=0.002) and coronary heart disease(HR=0.87, 95%CI: 0.79-0.96, P=0.005) than the control group at more than 2-year follow-up. There was no significant difference in the risk of ischemic stroke(HR=0.91, 95%CI: 0.82-1.01, P=0.081). For safety, the use of statins was not associated with the risk of diabetes(HR=0.95, 95%CI: 0.86-1.05, P=0.329), hepatic dysfunction(HR=0.81, 95%CI: 0.63-1.05, P=0.113), myopathy(HR=0.80, 95%CI: 0.55-1.17, P=0.25) or tumor(HR=0.98, 95%CI: 0.91-1.05, P=0.603) in adults aged 75 years and older.Conclusion: The use of statins for primary prevention of cardiovascular disease in adults aged 75 years or older could significantly reduce the risk of all-cause death, coronary heart disease, and major vascular events. Meanwhile, no increase in adverse reactions has been found. However, further research should be conducted for the effect of statins on ischemic stroke.
-
Key words:
- statin /
- aged /
- cardiovascular disease /
- primary prevention /
- Meta-analysis
-
-
[1] 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2019概要[J].中国循环杂志,2020,35(9):833-854.
[2] Kontis V,Bennett JE,Mathers CD,et al.Future life expectancy in 35 industrialised countries:projections with a Bayesian model ensemble[J].Lancet,2017,389(10076):1323-1335.
[3] Mortensen MB,Falk E.Primary prevention with statins in the elderly[J].J Am Coll Cardiol,2018,71(1):85-94.
[4] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study(4S)[J].Lancet,1994,344(8934):1383-1389.
[5] Shepherd J,Blauw GJ,Murphy MB,et al.Pravastatin in elderly individuals at risk of vascular disease(PROSPER):a randomised controlled trial[J].Lancet,2002,360(9346):1623-1630.
[6] Bibbins-Domingo K,Grossman DC,Curry SJ,et al.Statin use for the primary prevention of cardiovascular disease in adults:US Preventive Services Task Force Recommendation Statement[J].JAMA,2016,316(19):1997-2007.
[7] Gurwitz JH,Go AS,Fortmann SP.Statins for primary prevention in older adults:uncertainty and the need for more evidence[J].JAMA,2016,316(19):1971-1972.
[8] 中国心血管病一级预防指南[J].中华心血管病杂志,2020,48(12):1000-1038.
[9] Nicholls SJ,Nelson AJ.Statins for primary prevention in the elderly:the importance of rigorous evidence[J].JAMA,2020,324(1):45-46.
[10] Rabar S,Harker M,O'Flynn N,et al.Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease:summary of updated NICE guidance[J].BMJ,2014,349:g4356.
[11] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版).中华心血管病杂志[J],2016,44(10):833-853.
[12] Bittner V.The new 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease[J].Circulation,2020,142(25):2402-2404.
[13] Grundy SM,Stone NJ,Bailey AL,et al.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol:executive summary:a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines[J].Circulation,2019,139(25):e1046-e1081.
[14] Mach F,Baigent C,Catapano AL,et al.2019 ESC/EAS guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J].Eur Heart J,2020,41(1):111-188.
[15] 何旭瑜,杜明轩,黎励文.他汀类药物对老年人心血管事件一级预防的疗效及安全分析[J].中华老年心脑血管病杂志,2018,20(7):681-685.
[16] Ramos R,Comas-Cufí M,Martí-Lluch R,et al.Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes:retrospective cohort study[J].BMJ,2018,362:k3359.
[17] Orkaby AR,Driver JA,Ho YL,et al.Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older[J].JAMA,2020,324(1):68-78.
[18] Kim K,Lee CJ,Shim CY,et al.Statin and clinical outcomes of primary prevention in individuals aged>75 years:the SCOPE-75 study[J].Atherosclerosis,2019,284:31-36.
[19] Kim S,Choi H,Won CW.Effects of statin use for primary prevention among adults aged 75 years and older in the National Health Insurance Service Senior Cohort(2002-2015)[J].Ann Geriatr Med Res,2020,24(2):91-98.
[20] Bezin J,Moore N,Mansiaux Y,et al.Real-life benefits of statins for cardiovascular prevention in elderly subjects:a population-based cohort study[J].Am J Med,2019,132(6):740-748.e7.
[21] Eilat-Tsanani S,Mor E,Schonmann Y.Statin use over 65 years of age and all-cause mortality:a 10-year follow-up of 19518 people[J].J Am Geriatr Soc,2019,67(10):2038-2044.
[22] Orkaby AR,Gaziano JM,Djousse L,et al.Statins for primary prevention of cardiovascular events and mortality in older men[J].J Am Geriatr Soc,2017,65(11):2362-2368.
[23] Han BH,Sutin D,Williamson JD,et al.Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults:The ALLHAT-LLT randomized clinical trial[J].JAMA Intern Med,2017,177(7):955-965.
[24] Yusuf S,Bosch J,Dagenais G,et al.Cholesterol lowering in intermediate-risk persons without cardiovascular disease[J].N Engl J Med,2016,374(21):2021-2031.
[25] Ridker PM,Danielson E,Fonseca FA,et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J].N Engl J Med,2008,359(21):2195-2207.
[26] Gencer B,Marston NA,Im K,et al.Efficacy and safety of lowering LDL cholesterol in older patients:a systematic review and meta-analysis of randomised controlled trials[J].Lancet,2020,396(10263):1637-1643.
[27] Ridker PM,Lonn E,Paynter NP,et al.Primary prevention with statin therapy in the elderly:new meta-analyses from the Contemporary JUPITER and HOPE-3 randomized trials[J].Circulation,2017,135(20):1979-1981.
[28] Mortensen MB,Nordestgaard BG.Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years:a contemporary primary prevention cohort[J].Lancet,2020,396(10263):1644-1652.
[29] Giral P,Neumann A,Weill A,et al.Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years:a nationwide population-based cohort study in France[J].Eur Heart J,2019,40(43):3516-3525.
[30] Yebyo HG,Aschmann HE,Puhan MA.Finding the balance between benefits and harms when using statins for primary prevention of cardiovascular disease:a modeling study[J].Ann Intern Med,2019,170(1):1-10.
[31] Zhou Z,Albarqouni L,Curtis AJ,et al.The safety and tolerability of statin therapy in primary prevention in older adults:a systematic review and meta-analysis[J].Drugs Aging,2020,37(3):175-185.
[32] Cholesterol Treatment Trialists' Collaboration.Efficacy and safety of statin therapy in older people:a meta-analysis of individual participant data from 28 randomised controlled trials[J].Lancet,2019,393(10170):407-415.
[33] 彭道泉,杨阳.血脂管理与ASCVD的回顾与展望[J].临床心血管病杂志.2020,36(9):783-786.
-
计量
- 文章访问数: 500
- PDF下载数: 162
- 施引文献: 0
下载: